Rigel Pharmaceuticals, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company expected to report total revenue of approximately $51.3 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9414 USD | +2.62% | +4.24% | -35.08% |
05-07 | Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
05-07 | Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.08% | 161M | |
+8.92% | 114B | |
+10.48% | 104B | |
-1.83% | 22.57B | |
-6.45% | 22.5B | |
-10.39% | 17.95B | |
-42.36% | 16.48B | |
-14.45% | 15.82B | |
+3.76% | 13.55B | |
+28.94% | 10.99B |
- Stock Market
- Equities
- RIGL Stock
- News Rigel Pharmaceuticals, Inc.
- Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022